Literature DB >> 20192924

Correlation between serum biochemical markers and early amniocentesis in diagnosis of congenital fetal anomalies.

Dragan Loncar1, Mirjana Varjacic, Tanja Novakovic, Dragan Milovanovic, Slobodan Jankovic.   

Abstract

A combined test performed at the 12th week of gestation enables us to classify the pregnancy as high risk (risk higher than 1:300) or low risk (risk lower than 1:300) for congenital foetal anomalies, with great accuracy of 85 - 90%. According to the available data, the frequency of false positive results is estimated at around 5%. The objective of the study was to examine possible correlation between the serum marker values and amniocentesis results in prenatal diagnostics of congenital foetal anomalies. The study included 745 pregnant women monitored by the Genetic Counselling Service of the Clinic of Gynaecology and Obstetrics of the Clinics Centre Kragujevac. The subjects were included in the study under condition that CRL (embryonic crown-rump length) was from 45 to 84 mm and that the gestational age was at 11-13+6 weeks. Free beta HCG and PAPP-A were determined from venous blood using commercial DPS-USA tests. Tests were based on the analytic principle of the immuno-chemiluminescence technique and were performed by application of the automatic Immulite 2000 analyzer by DPC-USA. The foetal nuchal translucency thickness (NT) and CRL were measured by Colour Doppler. The chromosome identification was performed after a certain number of cell divisions by stopping the cell division in metaphase of mitosis when the chromosomes were the most distinguishable. The foetal karyotype was prepared using G bands. In the total sample of pregnant women (n=745), there were six cases of pathological foetal karyotype. A statistical paradox in the frequency of congenital foetal anomalies in favour of younger population was noticed. A high coefficient of Spearman's rank correlation suggests great importance of the combined test in the detection of congenital foetal anomalies (p<0,05). A high consistency was also proved for components of biochemical screening and ultrasonographic markers. The combined test, as a method of prenatal screening in the first trimester of pregnancy, if used at 11 - 13+6 weeks' gestation and for CRL of 45-84 mm, has a great importance in the detection of congenital foetal anomalies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192924      PMCID: PMC5596620          DOI: 10.17305/bjbms.2010.2726

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  14 in total

1.  Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.

Authors:  M A Zoppi; R M Ibba; M Floris; G Monni
Journal:  Ultrasound Obstet Gynecol       Date:  2001-12       Impact factor: 7.299

2.  Nuchal translucency and nasal bone for trisomy 21 screening: single center experience.

Authors:  Giovanni Monni; Maria A Zoppi; Rosa M Ibba; Marcella Floris; Fabiola Manca; Carolina Axiana
Journal:  Croat Med J       Date:  2005-10       Impact factor: 1.351

3.  Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.

Authors:  Kevin Spencer; Christina K H Yu; Nicholas J Cowans; Chineze Otigbah; Kypros H Nicolaides
Journal:  Prenat Diagn       Date:  2005-10       Impact factor: 3.050

4.  Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.

Authors:  E Pajkrt; J M van Lith; B W Mol; O P Bleker; C M Bilardo
Journal:  Ultrasound Obstet Gynecol       Date:  1998-09       Impact factor: 7.299

5.  Cell-free fetal DNA levels in pregnancies conceived by IVF.

Authors:  Phillip D Pan; Inga Peter; Geralyn M Lambert-Messerlian; Jacob A Canick; Diana W Bianchi; Kirby L Johnson
Journal:  Hum Reprod       Date:  2005-07-08       Impact factor: 6.918

6.  Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population.

Authors:  O Adekunle; A Gopee; M el-Sayed; B Thilaganathan
Journal:  Br J Radiol       Date:  1999-05       Impact factor: 3.039

7.  Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.

Authors:  Nicholas J Wald; Joan K Morris; Judith Ibison; Tiesheng Wu; Lynne M George
Journal:  Prenat Diagn       Date:  2006-06       Impact factor: 3.050

8.  One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.

Authors:  R Bindra; V Heath; A Liao; K Spencer; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2002-09       Impact factor: 7.299

9.  First-trimester pregnancy-associated plasma protein A and subsequent abnormalities of fetal growth.

Authors:  Suzanne E Peterson; Hyagriv N Simhan
Journal:  Am J Obstet Gynecol       Date:  2008-03-04       Impact factor: 8.661

Review 10.  Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.

Authors:  Kypros H Nicolaides
Journal:  Am J Obstet Gynecol       Date:  2004-07       Impact factor: 8.661

View more
  1 in total

1.  Evaluation of Preclinical and Clinical Studies Published in Medical Journals of Bosnia and Herzegovina: Methodology Issues.

Authors:  Slobodan M Jankovic; Izet Masic
Journal:  Acta Inform Med       Date:  2020-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.